# Mazdutide vs Survodutide: How They Differ | PepVault

Source: https://pepvault.app/peptides/compare/mazdutide-vs-survodutide

Last updated: 2026-10-06

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Library](https://pepvault.app/peptides) [Comparisons](https://pepvault.app/peptides/compare) Mazdutide vs Survodutide

Compared side by side

# Mazdutide vs survodutide: how they differ

Reviewed October 2026 [How we check the library](https://pepvault.app/about#library) [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The short answer

Both are weekly GLP-1 and glucagon dual agonists: mazdutide is built on oxyntomodulin, a gut hormone that acts on both receptors, and survodutide on the glucagon sequence, fully activating the GLP-1 receptor and partly the glucagon receptor. Mazdutide was approved in China in 2025 and isn’t FDA-approved; survodutide isn’t approved, and its phase 3 results were published in 2026. In phase 3, people lost about 11% (4 mg) and 14% (6 mg) of their weight at 48 weeks on mazdutide, and 12–13% at 76 weeks counting everyone on survodutide.

## Side by side

| Compared | [Mazdutide](https://pepvault.app/peptides/mazdutide) | [Survodutide](https://pepvault.app/peptides/survodutide) |
| --- | --- | --- |
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | IBI362, LY3305677, Xinermei | BI 456906, BI456906, Survo |
| What it is | A once-weekly GLP-1 and glucagon dual agonist from Innovent and Eli Lilly, approved in China in 2025 for weight management (as Xinermei) and type 2 diabetes; it is not FDA-approved. | A weekly shot that activates two receptors: GLP-1, for appetite and blood sugar, and glucagon, which clears fat from the liver and, in mice, raises energy use. |
| How it works | Once-weekly GLP-1 and glucagon receptor dual agonist built on oxyntomodulin, a gut hormone that acts on both receptors, with a C20 fatty-acid side chain that stretches its half-life to about 10 days. The GLP-1 arm curbs appetite; the glucagon arm adds energy expenditure (shown in mice). Developed by Innovent with Eli Lilly and approved in China in 2025 for weight management and type 2 diabetes. Its label steps the dose up every 4 weeks from 2 mg, and GI side effects come mostly during those step-ups. | Glucagon and GLP-1 receptor dual agonist: a 29-amino-acid peptide built on the glucagon sequence, carrying a C18 fatty acid that binds albumin for once-weekly dosing. It fully activates the GLP-1 receptor (appetite, insulin) and partly activates the glucagon receptor, which raises energy expenditure (shown in mice) and draws down liver fat (the liver-fat drop is measured in people). Developed by Boehringer Ingelheim with Zealand Pharma; its phase 3 (SYNCHRONIZE) results were published in 2026, and it is not approved. |
| Commonly reported | Strong appetite suppression and GI side effects after each step-up, much as with other weekly GLP-1s; user reports from outside China are still few. | Less appetite and early fullness, with nausea or vomiting during the long dose climb and a resting heart rate a few beats higher. Average weight loss at 76 weeks was 12–13% counting everyone and up to 16.6% for people who stayed on it, and most people in its liver trial cut their liver fat by at least 30%. |
| Studied range | Research range: 2–6 mg, starting dose 2 mg. Studied in research — not a recommendation. | Research range: 0.3–6 mg, starting dose 0.3 mg. Studied in research — not a recommendation. |
| How often | Weekly | Weekly |
| Half-life | ~10 days (Chinese label: the mean in people with obesity or overweight; about 8 days in type 2 diabetes) | Long enough for once-weekly dosing: a fatty-acid chain binds it to albumin; phase I measured it in people (Jungnik 2023), but the figure is not in the trial summaries |
| Route | SubQ injection | SubQ injection |
| Typical run | Used continuously, once weekly, in its trials and label. Per the label, a dose 1 to 3 weeks late (2 to 4 weeks since the last one) restarts one dose step lower, and more than 3 weeks late restarts the 2 mg step. No trial has tested stopping it. | Phase 3 trials run it continuously for 76 weeks after a slow climb of about 24 weeks. Not approved; Boehringer Ingelheim expects its cardiovascular outcomes trial to report later in 2026. |
| Evidence | Established: clinical trials or FDA-approved use exists | Established: clinical trials or FDA-approved use exists |
| Common side effects | Nausea, diarrhea, vomiting, abdominal bloating, abdominal pain, injection site reaction, dizziness, acid reflux | Nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, higher resting heart rate |

Typical run: Community practice — opinions vary. Not a clinical recommendation.

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking mazdutide or survodutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

### Mazdutide

- Day 1–28 · 2 mg Appetite first, scale later
- Day 29–56 · 4 mg A maintenance dose, not just a step
- Day 57–224 · 4 mg Holding at 4 mg
- Day 57–224 · 6 mg The top labelled dose
- Day 225–336 Weeks 32 to 48: still moving, more slowly
- Day 337+ A maintenance medication, not a course

[Every card for mazdutide, with its sources](https://pepvault.app/peptides/mazdutide#weeks)

### Survodutide

- Day 1–14 · 0.3 mg The 0.3 mg start
- Day 15–168 The slow climb
- Day 99+ · 3.6 mg 3.6 mg, the lower phase 3 dose
- Day 141+ · 6 mg 6.0 mg, the top phase 3 dose
- Day 169–336 Liver fat: where the glucagon arm shows

[Every card for survodutide, with its sources](https://pepvault.app/peptides/survodutide#weeks)

## With this comparison

### Mazdutide

- [Mazdutide: the full reference](https://pepvault.app/peptides/mazdutide)
- [Mazdutide dose guide](https://pepvault.app/lab/dosage/mazdutide)

### Survodutide

- [Survodutide: the full reference](https://pepvault.app/peptides/survodutide)
- [Survodutide dose guide](https://pepvault.app/lab/dosage/survodutide)

### Mixing charts

- [Mazdutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/mazdutide-10mg)
- [Survodutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/survodutide-10mg)

### Studies

- [Mazdutide: 16.65% average weight loss at 60 weeks in GLORY-2](https://pepvault.app/research/mazdutide-glory-2-2026)
- [Mazdutide beat dulaglutide on HbA1c and weight at 28 weeks](https://pepvault.app/research/mazdutide-guo-2026)
- [Mazdutide: HbA1c fell 2.15% at 24 weeks in type 2 diabetes](https://pepvault.app/research/mazdutide-zhu-2026)
- [All 4 studies](https://pepvault.app/research#mazdutide)
- [Survodutide: 12.2% weight loss and less liver fat at 48 weeks](https://pepvault.app/research/survodutide-synchronize-masld-2026)
- [Survodutide: up to 14.9% weight loss at 46 weeks in phase 2 trial](https://pepvault.app/research/survodutide-le-roux-2024)
- [All 2 studies](https://pepvault.app/research#survodutide)

### Compared with

- [Mazdutide vs Tirzepatide](https://pepvault.app/peptides/compare/mazdutide-vs-tirzepatide)
- [Retatrutide vs Mazdutide](https://pepvault.app/peptides/compare/retatrutide-vs-mazdutide)
- [Survodutide vs Retatrutide](https://pepvault.app/peptides/compare/survodutide-vs-retatrutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Subcutaneous (SubQ)](https://pepvault.app/glossary/subcutaneous)
- [Half-life](https://pepvault.app/glossary/half-life)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Glucagon](https://pepvault.app/glossary/glucagon)

## Questions people ask

### How long do mazdutide and survodutide last?

The half-life of mazdutide is ~10 days (Chinese label: the mean in people with obesity or overweight; about 8 days in type 2 diabetes). The half-life of survodutide is long enough for once-weekly dosing: a fatty-acid chain binds it to albumin; phase I measured it in people (Jungnik 2023), but the figure is not in the trial summaries.

### How often are mazdutide and survodutide taken?

Mazdutide: weekly. Route: SubQ injection. Survodutide: weekly. Route: SubQ injection.

### How are mazdutide and survodutide dosed in research?

The research range for mazdutide is 2–6 mg, with a 2 mg starting dose. The research range for survodutide is 0.3–6 mg, with a 0.3 mg starting dose. Studied in research — not a recommendation.

### What are the common side effects of mazdutide and survodutide?

For mazdutide, the library lists: nausea, diarrhea, vomiting, abdominal bloating, abdominal pain, injection site reaction, dizziness, acid reflux. For survodutide: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, higher resting heart rate.

## Each one in full

- [Mazdutide: dosage, half-life & reference guide](https://pepvault.app/peptides/mazdutide)
- [Survodutide: dosage, half-life & reference guide](https://pepvault.app/peptides/survodutide)
- [Mazdutide dose guide](https://pepvault.app/lab/dosage/mazdutide)
- [Survodutide dose guide](https://pepvault.app/lab/dosage/survodutide)

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking mazdutide or survodutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking mazdutide or survodutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this comparison

### Mazdutide

- [Mazdutide: the full reference](https://pepvault.app/peptides/mazdutide)
- [Mazdutide dose guide](https://pepvault.app/lab/dosage/mazdutide)

### Survodutide

- [Survodutide: the full reference](https://pepvault.app/peptides/survodutide)
- [Survodutide dose guide](https://pepvault.app/lab/dosage/survodutide)

### Mixing charts

- [Mazdutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/mazdutide-10mg)
- [Survodutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/survodutide-10mg)

### Studies

- [Mazdutide: 16.65% average weight loss at 60 weeks in GLORY-2](https://pepvault.app/research/mazdutide-glory-2-2026)
- [Mazdutide beat dulaglutide on HbA1c and weight at 28 weeks](https://pepvault.app/research/mazdutide-guo-2026)
- [Mazdutide: HbA1c fell 2.15% at 24 weeks in type 2 diabetes](https://pepvault.app/research/mazdutide-zhu-2026)
- [All 4 studies](https://pepvault.app/research#mazdutide)
- [Survodutide: 12.2% weight loss and less liver fat at 48 weeks](https://pepvault.app/research/survodutide-synchronize-masld-2026)
- [Survodutide: up to 14.9% weight loss at 46 weeks in phase 2 trial](https://pepvault.app/research/survodutide-le-roux-2024)
- [All 2 studies](https://pepvault.app/research#survodutide)

### Compared with

- [Mazdutide vs Tirzepatide](https://pepvault.app/peptides/compare/mazdutide-vs-tirzepatide)
- [Retatrutide vs Mazdutide](https://pepvault.app/peptides/compare/retatrutide-vs-mazdutide)
- [Survodutide vs Retatrutide](https://pepvault.app/peptides/compare/survodutide-vs-retatrutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Subcutaneous (SubQ)](https://pepvault.app/glossary/subcutaneous)
- [Half-life](https://pepvault.app/glossary/half-life)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Glucagon](https://pepvault.app/glossary/glucagon)

<!--promo-->

PepVault for iPhone

## Taking mazdutide or survodutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## More comparisons

- [All peptide comparisons](https://pepvault.app/peptides/compare)
- [Mazdutide vs Tirzepatide](https://pepvault.app/peptides/compare/mazdutide-vs-tirzepatide)
- [Survodutide vs Retatrutide](https://pepvault.app/peptides/compare/survodutide-vs-retatrutide)
- [Retatrutide vs Mazdutide](https://pepvault.app/peptides/compare/retatrutide-vs-mazdutide)
- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)

## The library

- [The peptide reference library](https://pepvault.app/peptides)
- [Metabolic & GLP-1 peptides](https://pepvault.app/peptides#metabolic)

## Free tools

- [The Dose Guide](https://pepvault.app/lab/dosage)
- [Half-life & active level](https://pepvault.app/tools/peptide-half-life-calculator)
- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
